XML 100 R40.htm IDEA: XBRL DOCUMENT
v3.20.1

ORGANIZATION AND BASIS OF PRESENTATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Subsidiaries |
| (a) |  | Details of the Company’s principle subsidiaries as of December 31, 2019 are as follows:
|  |  |  |  |  | Percentage of |  |
|  | Date of |  | Place of |  | ownership by |  |
Entities |  | establishment/acquisition |  | establishment |  | the Company |  | Principal activities
Subsidiaries |  |  |  |  |  |  |  |
Ascendium Group Limited (“Ascendium”) |  | September 10, 2007 |  | British Virgin Islands (“BVI”) |  | 100 | % | Investment holding
China Medical Services Holdings Limited (“CMS Holdings”) |  | July 18, 2008 |  | Hong Kong |  | 100 | % | Investment holding
King Cheers Holdings Limited (“King Cheers”) |  | May 18, 2001 |  | Hong Kong |  | 100 | % | Investment holding
Shenzhen Aohua Medical Technology Development Co., Ltd. (“Aohua Technology ”) |  | February 21, 2008 |  | PRC |  | 60 | % | Leasing of medical equipment and provision of management services
Shanghai Medstar Financial Leasing Company Limited ("Shanghai Medstar") |  | March 21, 2003 |  | PRC |  | 100 | % | Leasing of medical equipment and provision of management services
Beijing MeizhongJiahe Hospital Management Co., Ltd. (“MHM”) * |  | July 23, 2008 |  | PRC |  | 60 | % | Provision of management services
Beijing Yundu Internet Technology Co., Ltd. (“Yundu”) |  | July 26, 2007 |  | PRC |  | 60 | % | Provision of management services
Tianjin Concord Medical Technology Limited (“Tianjin Concord Medical”) |  | April 22, 2010 |  | PRC |  | 100 | % | Leasing of medical equipment and provision of management services
Guangzhou Jinkangshenyou Investment Co., Ltd. (“JKSY”) |  | August 12, 2010 |  | PRC |  | 100 | % | Leasing of medical equipment and provision of management services
Guangzhou Concord Cancer Center Co., Ltd ("Guangzhou Concord Cancer Hospital") |  | June 29, 2011 |  | PRC |  | 48 | % | Medical treatment and service business
CCM (Hong Kong) Medical Investments Limited (“CCM (HK)”) |  | June 03, 2013 |  | Hong Kong |  | 100 | % | Investment holding
Shanghai Concord Cancer Center Co., Ltd (“SHC”) |  | March 17, 2014 |  | PRC |  | 60.26 | % | Medical treatment and service business
Datong Meizhong Jiahe Cancer Center (“DTMZ”) |  | October 23, 2014 |  | PRC |  | 60 | % | Medical treatment and service business
Wuxi Concord Medical Development Ltd. ("Wuxi Concord”) |  | December 29, 2015 |  | PRC |  | 100 | % | Provision of management services
|  |  |  |  |  | Percentage of |  |
|  | Date of |  | Place of |  | ownership by |  |
Entities |  | establishment/acquisition |  | establishment |  | the Company |  | Principal activities
Beijing Concord Medical Technology Ltd.(“BJCMT”) |  | January 4, 2016 |  | PRC |  | 100 | % | Provision of management services
Guofu Huimei (Tianjin) Investment Management Partnership Firm (LP) (“Guofu Huimei”) (note 4) |  | October 8, 2018 |  | PRC |  | 100 | % | Investment holding
Beijing Century Friendship Science & Technology Development Co., Ltd (“Beijing Century Friendship”) (note 4) |  | October 8, 2018 |  | PRC |  | 60 | % | Provision of management services and investment holding
Beijing Proton Medical Center Co., Ltd (“BPMC”) (note 4) |  | October 8, 2018 |  | PRC |  | 58 | % | Medical treatment and service business
Shanghai Meizhong Jiahe Cancer Center Co., Ltd. (“CMCC”) (note 4) |  | October 8, 2018 |  | PRC |  | 55.42 | % | Medical treatment and service business
Tianjin Jiatai Entity Management Limited Partnership ("Tianjin Jiatai") (note 4) |  | November 18,2019 |  | PRC |  | 100 | % | Investment holding
Shanghai Rongchi Medical Management Limited ("SH Rongchi") (note 4) |  | November 18,2019 |  | PRC |  | 99.90 | % | Investment holding and provision of management services
Oriental Light Group Limited ("Oriental") (note 4) |  | November 18,2019 |  | BVI |  | 99.90 | % | Investment holding
Shanghai Meizhong Jiahe Imaging Diagnostic Center Co., Ltd. ("SH MZJH") (note 4) |  | November 18,2019 |  | PRC |  | 93.15 | % | Medical treatment and service business
Wuxi Meizhong Jiahe Cancer Center Co., Ltd. ("Wuxi MZJH") (note 4) |  | November 18,2019 |  | PRC |  | 98.93 | % | Medical treatment and service business
Heze Meizhong Jiahe Cancer Center Co., Ltd. ("Heze MZJH") (note 4) |  | November 18,2019 |  | PRC |  | 100 | % | Medical treatment and service business
ZR ConcordHealthcare Investment Fund SP (“SP”) |  | November 2016 |  | Cayman Islands |  | 99.93 | % | Investment holding
US Proton Therapy Holdings Limited (“Proton BVI”) |  | May 16, 2011 |  | BVI |  | 99.93 | % | Investment holding
US Proton Therapy Holdings Limited (“US Proton”) |  | June 29, 2011 |  | United States of America |  | 99.93 | % | Investment holding
Concord Medical Services (International) Pte. Ltd. (“China Medstar”) (formerly known as China Medstar Pte. Limited) |  | August 8, 2003 |  | Singapore |  | 99.93 | % | Investment holding
Concord Healthcare Singapore Pte. Ltd. (“CHS”) |  | April 1, 2015 |  | Singapore |  | 99.93 | % | Medical treatment and service business
*On March 26, 2018 and July 10, 2018, the Group entered into agreements with CICC Capital Management Company Limited (“CICC Capital”), a wholly-owned subsidiary of China International Capital Corporation Limited (“CICC”), and six other investors (“Other Investors”). Pursuant to the agreements, CICC Capital and Other Investors make a strategic investment and subscribe new issued 100,000,000 shares of the Group’s subsidiary MHM, with total consideration of RMB1,500,000 . CCIC Capital subscribes 60,000,000 shares of MHM while Other Investors subscribe 40,000,000 shares of MHM.
Schedule of financial information | The following tables represent the financial information of the VIE and its subsidiaries as of December 31, 2018 and 2019 and for the years ended December 31, 2018 and 2019 before eliminating the intercompany balances and transactions between the VIE and its subsidiaries and other entities within the Group (the net revenue, net loss and cashflow information for the whole year 2019 instead of for the period from January 1 to November 18, 2019 was presented since the results are not materially different):
|  | As at December 31,
|  | 2018 |  | 2019 |  | 2019
|  | RMB |  | RMB |  | US$
ASSETS |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash |  | 15,935 |  | — |  | —
Accounts receivable |  | 4,494 |  | — |  | —
Inventories |  | 1,946 |  | — |  | —
Prepayments and other current assets |  | 1,986 |  | — |  | —
Amount due from inter-companies* |  | 80,523 |  | — |  | —
Total current assets |  | 104,884 |  | — |  | —
Non-current assets: |  |  |  |  |  |
Property, plant and equipment, net |  | 281,395 |  | — |  | —
Intangible assets, net |  | 100 |  | — |  | —
Long-term investments |  | 31,496 |  | — |  | —
Other non-current assets |  | 464 |  | — |  | —
Total non-current assets |  | 313,455 |  | — |  | —
Total assets |  | 418,339 |  | — |  | —
|  | As at December 31,
|  | 2018 |  | 2019 |  | 2019
|  | RMB |  | RMB |  | US$
Current liabilities: |  |  |  |  |  |
Accounts payable |  | 462 |  | — |  | —
Accrued expenses and other liabilities |  | 42,681 |  | — |  | —
Income tax payable |  | 2,870 |  | — |  | —
Total current liabilities |  | 46,013 |  | — |  | —
Non-current liabilities: |  |  |  |  |  |
Accrued unrecognized tax benefits and surcharge, non-current portion |  | 20,208 |  | — |  | —
Mandatorily redeemable noncontrolling interests |  | 434,216 |  | — |  | —
Total non-current liabilities |  | 454,424 |  | — |  | —
Total liabilities |  | 500,437 |  | — |  | —
|  | For the Years Ended December 31,
|  | 2017 |  | 2018 |  | 2019 |  | 2019
|  | RMB |  | RMB |  | RMB |  | US$
Net revenues |  | 28,673 |  | 41,350 |  | 34,196 |  | 4,912
Net loss |  | (141,188) |  | (95,788) |  | (114,225) |  | (16,407)
|  | For the Years Ended December 31,
|  | 2017 |  | 2018 |  | 2019 |  | 2019
|  | RMB |  | RMB |  | RMB |  | US$
Net cash used in operating activities |  | (54,113) |  | (260,884) |  | (24,640) |  | (3,539)
Net cash generated from (used in) investing activities |  | (5,582) |  | 221,130 |  | (10,107) |  | (1,452)
Net cash generated from financing activities |  | 56,787 |  | 41,886 |  | 20,820 |  | 2,991
Exchange rate effect on cash, net |  | 748 |  | 600 |  | 304 |  | 44
Decrease (increase) in cash and cash equivalents |  | (2,160) |  | 2,732 |  | (13,623) |  | (1,957)

X
- Definition Schedule Of Subsidiaries And Principal Activities [Table Text Block] + References No definition available. + Details
Name: | ccm_ScheduleOfSubsidiariesAndPrincipalActivitiesTableTextBlock
Namespace Prefix: | ccm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration